Search Results

You are looking at 271 - 280 of 493 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Modern Approaches to Localized Cancer of the Esophagus

Robert E. Glasgow, David H. Ilson, James A. Hayman, Hans Gerdes, Mary F. Mulcahy, and Jaffer A. Ajani

over surgery alone in esophageal and gastroesophageal junction adenocarcinoma and squamous cancer. 45 This trial also used a more contemporary chemotherapy regimen: weekly carboplatin plus paclitaxel. Preoperative therapy conferred a median 2-year

Full access

NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018

A. Dimitrios Colevas, Sue S. Yom, David G. Pfister, Sharon Spencer, David Adelstein, Douglas Adkins, David M. Brizel, Barbara Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, David W. Eisele, Moon Fenton, Robert L. Foote, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Wesley L. Hicks Jr, Ying J. Hitchcock, Antonio Jimeno, Debra Leizman, Ellie Maghami, Loren K. Mell, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, James Rocco, Cristina P. Rodriguez, Jatin P. Shah, Randal S. Weber, Matthew Witek, Frank Worden, Weining Zhen, Jennifer L. Burns, and Susan D. Darlow

cisplatin/5-FU or cisplatin/paclitaxel. 49 However, results from a recent randomized phase III trial showed that patients with recurrent or metastatic NPC (N=362) who received gemcitabine/cisplatin had a greater median PFS compared with those who received

Full access

NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Noah Hahn, Harry W. Herr, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Joshua J. Meeks, Jeff Michalski, Jeffrey S. Montgomery, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Daniel P. Petrylak, Elizabeth R. Plimack, Kamal S. Pohar, Michael P. Porter, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Geoffrey Wile, Alyse Johnson-Chilla, Mary A. Dwyer, and Lisa A. Gurski

to treat MIBC. 20 , 21 , 26 – 31 The following radiosensitizing regimens are recommended: cisplatin/5-FU, cisplatin/paclitaxel, 5-FU/mitomycin C, and cisplatin alone; doublet chemotherapy is generally preferred. Low-dose gemcitabine (category 2B) may

Full access

NCCN Guidelines® Insights: Breast Cancer, Version 4.2023

Featured Updates to the NCCN Guidelines

William J. Gradishar, Meena S. Moran, Jame Abraham, Vandana Abramson, Rebecca Aft, Doreen Agnese, Kimberly H. Allison, Bethany Anderson, Harold J. Burstein, Helen Chew, Chau Dang, Anthony D. Elias, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Sara A. Hurvitz, Rachel C. Jankowitz, Sara H. Javid, Jairam Krishnamurthy, A. Marilyn Leitch, Janice Lyons, Joanne Mortimer, Sameer A. Patel, Lori J. Pierce, Laura H. Rosenberger, Hope S. Rugo, Bryan Schneider, Mary Lou Smith, Hatem Soliman, Erica M. Stringer-Reasor, Melinda L. Telli, Mei Wei, Kari B. Wisinski, Jessica S. Young, Kay Yeung, Mary A. Dwyer, and Rashmi Kumar

=847) with locally recurrent, inoperable, or metastatic TNBC and who were disease-free for ≥6 months were randomized to chemotherapy (albumin-bound paclitaxel, paclitaxel, or gemcitabine and carboplatin) ± pembrolizumab. In terms of PFS among patients

Full access

Ampullary Adenocarcinoma, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology

E. Gabriela Chiorean, Marco Del Chiaro, Margaret A. Tempero, Mokenge P. Malafa, Al B. Benson III, Dana B. Cardin, Jared A. Christensen, Vincent Chung, Brian Czito, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Christos Fountzilas, Evan S. Glazer, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Ashiq Masood, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Lorenzo Nardo, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Mark J. Truty, Charles Vollmer Jr, Robert A. Wolff, Brian M. Wolpin, Beth McCullough RN, Senem Lubin, and Susan D. Darlow

/mixed-type ampullary cancer include FOLFIRINOX/modified FOLFIRINOX (mFOLFIRINOX), gemcitabine + cisplatin, gemcitabine + capecitabine, and gemcitabine + albumin-bound paclitaxel. The NCCN-recommended neoadjuvant therapy options for intestinal type ampullary cancer

Full access

Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Apar Kishor P. Ganti, Billy W. Loo Jr., Michael Bassetti, Collin Blakely, Anne Chiang, Thomas A. D'Amico, Christopher D'Avella, Afshin Dowlati, Robert J. Downey, Martin Edelman, Charles Florsheim, Kathryn A. Gold, Jonathan W. Goldman, John C. Grecula, Christine Hann, Wade Iams, Puneeth Iyengar, Karen Kelly, Maya Khalil, Marianna Koczywas, Robert E. Merritt, Nisha Mohindra, Julian Molina, Cesar Moran, Saraswati Pokharel, Sonam Puri, Angel Qin, Chad Rusthoven, Jacob Sands, Rafael Santana-Davila, Michael Shafique, Saiama N. Waqar, Kristina M. Gregory, and Miranda Hughes

. 107 , 108 Similarly, the addition of paclitaxel to either cisplatin or carboplatin plus etoposide yielded promising results in phase 2 trials, but did not improve survival and was associated with unacceptable toxicity in a phase III study. 109 The

Full access

Molecular Biomarkers in Gastric Cancer

Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Kazuki Sudo, Jeannelyn S. Estrella, Brian D. Badgwell, Prajnan Das, Aurelio Matamoros Jr, Shumei Song, and Jaffer A. Ajani

to be seen and is being tested in an ongoing phase II trial comparing AZD4547 with paclitaxel in the second-line setting in patients with FGFR2 polysomy or amplification ( identifier: NCT01457846). HER2 In GC, ERBB2

Full access

Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

Ronald C. Chen, William U. Shipley, Jason A. Efstathiou, and Anthony L. Zietman

: cisplatin alone, cisplatin/5-FU, or cisplatin/paclitaxel ( Table 1 ).The recently published BC2001 trial provides an alternative regimen for patients who are noncisplatin candidates either due to poor renal function or concerns about cisplatin tolerability

Full access

Second-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancers

Helena A. Yu and Gregory J. Riely

adenocarcinoma who were former light or never smokers (the key clinical characteristics associated with response to EGFR TKI and presence of EGFR mutations) to receive either gefitinib or the combination of carboplatin and paclitaxel as first-line treatment. 7

Full access

Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course

Jocelyn S. Chapman, Saurabh Asthana, Lindsay Cade, Matthew T. Chang, Zhen Wang, Charles J. Zaloudek, Stefanie Ueda, Eric A. Collisson, and Barry S. Taylor

-bound paclitaxel therapy. 8 Results of this CT showed evolving findings, including ascites with peritoneal thickening, a complex 6.1-cm right adnexal lesion, and the absence of a discrete pancreatic mass, which was reinterpreted as a lymph node conglomerate